報價延遲最少15分鐘:2025/06/04 05:23 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.84 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.67/-2.64
|
|
企業價值
574.57M
|
| 資產負債 |
|
每股賬面淨值
8.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.21M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 05:23 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. |